Request Demo

Last update 25 Mar 2025

Finasteride

Last update 25 Mar 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryFinasteride, marketed under the trade name PROSCAR®, is a 5α-reductase inhibitor used primarily for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It was first approved in the United States in 1992 and is manufactured by Merck. Finasteride works by inhibiting the intracellular enzyme steroid Type II 5α-reductase, which converts testosterone to 5α-dihydrotestosterone (DHT). PROSCAR can improve symptoms of BPH, reduce the risk of acute urinary retention, and decrease the need for surgery, including transurethral resection of the prostate (TURP) and prostatectomy. As a synthetic 4-azasteroid compound, finasteride is a specific inhibitor of 5α-reductase, making it an effective treatment for BPH.

Drug Type

Small molecule drug

Synonyms

(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide, Finasteride (JAN/USP/INN), 非那雄胺（奎安）

+ [47]

Target

5α-reductase

Action

inhibitors

Mechanism

5α-reductase inhibitors(Steroid 5 alpha reductase inhibitors)

Therapeutic Areas

Skin and Musculoskeletal DiseasesUrogenital Diseases

Active Indication

Androgenetic AlopeciaAlopeciaProstatic Hyperplasia

Inactive Indication

Alopecia, Male PatternHematuriaHemospermia

Originator Organization

Merck & Co., Inc.

Active Organization

Youngil Pharm

Organon & Co.Kedi Biomedical (Wuxi) Co., Ltd.

+ [4]

Inactive Organization

Merck Frosst Canada Ltd.Polichem SA (Switzerland)

Nanjing Sanhome Pharmaceutical Co. Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (19 Jun 1992),

Prostatic Hyperplasia

Regulation-

Structure/Sequence

Molecular FormulaC23H36N2O2

InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N

CAS Registry98319-26-7

140

Clinical Trials associated with Finasteride

NCT06826001

/ Not yet recruitingPhase 2IIT

COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA

Androgenetic alopecia (AGA)is the most common form of alopecia. It predominantly affects males, but there has been a significant surge in female preponderance too, over the last decade Minoxidil belong to the anti-hypertensive class but it also affects the potassium channels present in vascular smooth muscles and hair follicles. This potassium channel activity may stimulate the microcirculation around the hair follicles and induces arteriolar vasodilation, thereby encouraging conditions conducive to hair growth Topical administration of finasteride offers the potential to reduce systemic effects related to its mechanism of action by preferentially inhibiting 5-a reductase in the scalp, as has been suggested in recent years so in this study we are going to compare efficacy of topical minoxidil versus topical finasteride in treatment of androgenetic alopecia

Start Date01 Feb 2025

Sponsor / Collaborator

Sheikh Zayed Medical College

IRCT20180620040164N71

/ CompletedNot Applicable

Comparative bioequivalence study of Finasteride 5 mg Tablet of Iran Hormone. and Finasteride® of 1A Pharma GmbH as reference in 24 healthy male under fasting.

Start Date25 Nov 2024

Sponsor / Collaborator

Iran Hormone Co.

NCT06590779

/ Not yet recruitingNot Applicable

Evaluation of the Benefits of a Cosmetic Anti-hair Loss Lotion Applied in Combination With Finasteride in Male Subjects With Hair Loss: Investigator-blinded, Randomized, Multi-center Study Performed Under Dermatological Control

Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. AGA is a polygenetic condition with varying severity, age of onset, and scalp location of hair loss. In men, hair loss typically involves the temporal and vertex region while sparing the occipital region: the characteristic "horseshoe" pattern. Incidence and prevalence of AGA depend on age and race.
Vichy has developed a new cosmetic anti hair loss lotion with the aim of acting on androgenic alopecia. The aim is to improve the efficacy on hair loss of the association of the lotion with finasteride versus finasteride alone.
The primary objective of this investigator-blinded, randomized multi-center study is to quantitatively evaluate, using the phototrichogram method, the efficacy of a lotion associated with finasteride versus finasteride alone on hair growth parameters in male subjects with androgenetic alopecia.

Start Date02 Nov 2024

Sponsor / Collaborator

Cosmetique Active International

[+2]

100 Clinical Results associated with Finasteride

100 Translational Medicine associated with Finasteride

100 Patents (Medical) associated with Finasteride

4,215

Literatures (Medical) associated with Finasteride

04 Mar 2025·Expert Opinion on Drug Delivery

An update on nanocarriers for follicular-targeted drug delivery for androgenetic alopecia topical treatment

Review

Author: Gratieri, Taís ; Bakst, Andrew ; Andrade, Jayanaraian F. M. ; Verbinnen, Andrew ; Cunha-Filho, Marcilio ; Gelfuso, Guilherme M.

INTRODUCTION:

Androgenic alopecia is a multifactorial disease with a high incidence and a great psychological burden on patients. The current FDA-approved treatment is topical minoxidil or oral finasteride. However, both present significant limitations. While the systemic absorption of finasteride causes serious sexual side effects, minoxidil's low solubility imposes a challenge in obtaining a non-irritative and effective formulation. One way to solve such limitations is by using nanocarriers targeting the drug delivery to the hair follicles upon topical application.

AREAS COVERED:

Here, we review which advancements have been made to achieve a more effective treatment for androgenic alopecia, focusing on nanocarriers for the topical drug delivery systems developed to target hair follicles.

EXPERT OPINION:

The results from multiple reviewed studies demonstrate the potential of incorporating drugs into different nanocarriers to improve follicular targeting in drug delivery for androgenic alopecia treatment. However, many studies fail to perform the proper controls. Most studies also do not quantify the drug accumulation in all skin layers, especially in hair follicles, which avoids comparisons between different nanocarriers and, hence, reliable conclusions. Future experiments with a broader nanocarrier size range, suitable skin models and controls, and clinical tests to assess the safety of developed formulations will improve the androgenic alopecia treatment.

04 Mar 2025·Therapeutic Delivery

Topical dutasteride for androgenic alopecia: current state and prospects

Review

Author: Gratieri, Taís ; Bakst, Andrew ; Andrade, Jayanaraian F. M. ; Cunha-Filho, Marcílio ; Verbinnen, Andrew ; Gelfuso, Guilherme M.

Androgenic alopecia has a high incidence, affecting 80% of men and 50% of women in their lifetimes. Although not a life-threatening disease, it can be a deep psychological burden to patients and still lacks an effective and safe treatment. Dutasteride is a5-alpha-reductase inhibitor approved to treat benign prostatic hyperplasia that is also commonly prescribed off-label to treat androgenic alopecia. However, oral dutasteride may cause several severe sexual and neurological sideeffects. Therefore, an effective, localized dutasteride treatment that can reduce the effects of systemic uptake is of great interest. Here, we review available therapies to treat androgenic alopecia focusing on topicalformulations developed thus far-including minoxidil, finasteride, and cosmetics-and on dutasteride-loaded nanocarriers targeting hair follicles.

04 Mar 2025·Natural product research

Anti-BPH lignans from Urtica triangularis subsp. pinnatifida (Hand.-Mazz.) C.J.Chen

Article

Author: Zhang, Xinyi ; Xiao, Dongliang ; Luosang, Dunzhu ; Yan, Hai ; Xi, Yufei ; Cidan, Yangji ; Jiang, Nan ; Fu, Qing ; Lu, Xuan ; Feng, Baomin

A new lignan named (-)-ginkgool-9-O-β-glucopyranoside (1) together with eight known lignans (2-9) were isolated from Urtica triangularis subsp. pinnatifida (Hand.-Mazz.) C.J.Chen. According to the mass spectrometry and spectroscopic analyses, the gross structure and absolute configuration of the new lignan were elucidated. The cytotoxic effects of compounds 1-9 on BPH-1 cells and the docking results on type II 5α-reductase were analysed to evaluate their anti-BPH activity. The results showed better anti-BPH activity that compound 4 displaying an IC₅₀ of 79.75 ± 3.68 μM than finasteride presenting an IC₅₀ of 91.8 ± 3.74 μM. Compounds 1, 2 and 5 had moderate anti-BPH activity compared with finasteride.

News (Medical) associated with Finasteride

19 Mar 2025

·www.globenewswire.com

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that an abstract has been accepted for presentation at the 2025 European Association of Urology (EAU) congress taking place March 21-24, 2025, in Madrid, Spain. The presentation, titled, “Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer: Evaluation in a Danish Cohort,” will highlight Proclarix performance results recently obtained from a study including more than 800 patients recruited from Lillebaelt Hospital - University Hospital of Southern Denmark. “The abstract accepted for presentation at EAU congress will showcase the importance of early detection of prostate cancer, particularly using Proclarix, a biomarker-based blood test,” stated Ralph Schiess, PhD, CEO of Proteomedix, a wholly-owned subsidiary of Onconetix, and added: “Proclarix has already demonstrated in multiple studies that it can be safely used to reduce performed biopsies by ruling out patients with clinically insignificant or no prostate cancer while minimizing the risk of missing clinically significant cancer when compared to standard of care.” Details on the presentation are as follows: Presentation Title:Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer: Evaluation in a Danish CohortPresenter:Zedan Raid A.H, Lillebaelt Hospital - University Hospital of Southern Denmark, Department of Oncology, Vejle, DenmarkSession Title:Diagnostic and prognostic biomarkers in prostate cancerDate and Time:March 23, 2025, from 5:15 PM to 6:45 PM CET About Proclarix® Proclarix® is CE-certified under In Vitro Diagnostic Regulation (“IVDR”) and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix® is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix® risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer. Proclarix® is included in both the European (EAU) and American (AUA) guidelines. About Onconetix, Inc. Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology. Through our recent acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union (“EU”) under the IVDR, which we anticipate will be marketed in the U.S. as a lab developed test (“LDT”) through our license agreement with Labcorp. We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia (“BPH”), a disorder of the prostate. For more information, visit www.onconetix.com. Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the anticipated results of the Company’s sales and marketing efforts for its commercial stage products as described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, market and other conditions; risks related to Onconetix’s ability to commercialize or monetize Proclarix and integrate the assets and commercial operations acquired in the share exchange with Proteomedix; risks related to the Company’s present need for capital to commercially launch Proclarix and have adequate working capital; risks related to Onconetix’s ability to attract, hire and retain skilled personnel necessary to commercialize and operate the Company’s commercial products; the failure to obtain and maintain the necessary regulatory approvals to market and commercialize Onconetix’s products; risks related to the Company’s ability to obtain and maintain intellectual property protection for its current products; whether the Company will be able to maintain compliance with Nasdaq’s applicable listing criteria and the effect of a delisting from Nasdaq on the market for the Company’s securities; and the Company’s reliance on third parties, including manufacturers and logistics companies. As with any commercial-stage pharmaceutical product or any product candidate under clinical development, there are significant risks in the development, regulatory approval and commercialization of biotechnology products. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K, filed with the SEC on April 11, 2024 and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor and Media Contact Information: Onconetix, Inc. 201 E. Fifth Street, Suite 1900 Cincinnati, OH 45202 Phone: (513) 620-4101 Investor Contact Information: Onconetix Investor Relations Email: investors@onconetix.com

License out/inAcquisitionDrug Approval

08 Jan 2025

·www.prnewswire.com

Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results

Demonstrates Potential for ET-02 to be Significantly More Effective Than Existing Treatments for Hair Loss WOBURN, Mass., Jan. 8, 2025 /PRNewswire/ -- Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, announced today the successful results of its first-in-man clinical trial for the treatment of androgenic alopecia (age-related hair loss) using its topical pharmaceutical ET-02. Jon Edelson, MD, CEO and President of Eirion, commented "80 million people in the United States suffer from hair loss and there is no truly effective treatment for this condition today. Because of ET-02's unique mechanism of action, we believe that ET-02 has the potential to not only treat but prevent androgenic alopecia. The results of this clinical trial show we are an important step closer to potentially having a solution for hair loss." In a double-blind, placebo-controlled, dose-ranging clinical study of 24 subjects at three U.S. investigational sites, three equal-sized groups were treated once daily for 4 weeks with either a control treatment comprised of the product vehicle, a 1.25% solution of ET-02 or a 5% solution of ET-02. A final assessment of the subjects was made one week after the treatments ended. Key results of the study showed: Safety: ET-02 was found to be safe and well tolerated. Dose-Response: A dose-response effect was observed, with minimal response observed in the vehicle and 1.25% ET-02 groups compared to the significant response observed in the higher dose 5% ET-02 group. Thus, for analysis, the placebo group was the combined vehicle and 1.25% ET-02 dose groups. Hair Growth: 5% ET-02 resulted in a 6-fold increase in non-vellus (or normal) hair count compared to the placebo group at the end of the fifth week of the study. For comparative purposes, after one month of treatment 5% ET-02 demonstrated more non-vellus hair growth than topical minoxidil produced after 4 months of treatment as measured in a separate clinical trial of minoxidil (N=180), the current "gold standard" treatment for androgenic alopecia. Hair Width: 5% ET-02 resulted in an approximately ten percentage point improvement in non-vellus hair width over the placebo group, which was essentially unchanged. Eirion's first-in-man study results confirm the efficacy of 5% ET-02 as demonstrated in a previous controlled pre-clinical study of topical 5% ET-02 treating 60 human scalp tissue grafts from men with androgenic alopecia. In that study, ET-02 was markedly more effective than the control group. The net rate of hair growth produced by ET-02 in the fourth month of treatment was four times greater than the amount produced by minoxidil in a second, separate pre-clinical study (N=103) using the same experimental graft model. Eirion plans to begin a Phase 2 clinical trial (N≈150) in 2025 with a 6-month treatment period with the goal of confirming ET-02's safety and efficacy. Jerry Shapiro, MD, a leading expert on the treatment of hair loss and Professor of Dermatology at New York University Grossman School of Medicine noted that "Eirion's clinical trial results are clear-cut and remarkable. Achieving this amount of hair growth in just 5 weeks in a clinical trial is unprecedented. ET-02 represents a potentially substantial advancement over minoxidil and other commercially available pharmaceuticals for patients struggling with hair loss, not only from an efficacy standpoint, but also from safety and ease-of-use standpoints. Due to its non-hormonal mechanism of action, ET-02 is not expected to have the same side effects that patients complain of, like sexual dysfunction, for androgen inhibition treatments like finasteride. ET-02 is being tested as a once-a-day treatment, rather than the less convenient twice-a-day regimen required for topical minoxidil." Dr Shapiro added, "I look forward to future clinical studies of ET-02." ET-02 has a novel mechanism of action which restores normal function to hair follicle stem cells that have become inactive in age-related hair loss due to a defect that develops in the stem cell biology. Hair follicle stem cells are known to be the "master control switches" for hair growth. By correcting this defect and returning the stem cells to normal activity and function, the expectation is that hair growth can be restored. Eirion expects ET-02 has the potential to be significantly more effective than existing treatments since it directly addresses what Eirion believes is the fundamental cause of androgenic alopecia, while existing treatments do not. Eirion also believes ET-02 has the potential to treat and prevent hair greying by impacting in a similar manner the melanocyte stem cells which control the production of hair color. Eirion Therapeutics will participate in the Aesthetics Tech Forum taking place January 9 – 10, 2025, in Newport Beach, California. Dr Edelson will present an update on Eirion and clinical trial results during the conference session "Company Presentations" that will take place on Thursday January 9th 1:25 PM – 2:30 PM PST. About Eirion Therapeutics, Inc. Eirion Therapeutics, Inc. is a privately held, clinical stage biopharmaceutical company that is developing next-generation prescription products for aesthetic medicine. Eirion currently has a rich pipeline of product candidates focusing on treatments for wrinkles, androgenic alopecia, hair greying and primary axillary hyperhidrosis. Eirion's product candidates, all of which have been studied in one or more clinical trials, include AI-09 liquid injectable neuromodulator, ET-01 topical neuromodulator, and ET-02 topical small molecule. To learn more about Eirion, please visit: Media Contact Megan Driscoll EvolveMKD [email protected] SOURCE Eirion Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 2

12 Dec 2024

·www.globenewswire.com

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6, 2024 indicating that the Company’s failure to file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”) is in violation of Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”). On December 10, 2024, the Company filed the Form 10-Q with the Securities and Exchange Commission. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. About Onconetix, Inc.: Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology. Through our recent acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union (“EU”) under the In Vitro Diagnostic Regulation (“IVDR”). We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia (“BPH”), a disorder of the prostate. For more information, visit www.onconetix.com. Contact Information: Onconetix, Inc.201 E. Fifth Street, Suite 1900Cincinnati, OH 45202Phone: (513) 620-4101 Investor Contact Information: Onconetix Investor RelationsEmail: investors@onconetix.com

AcquisitionDiagnostic Reagents

100 Deals associated with Finasteride

External Link

KEGG	Wiki	ATC	Drug Bank
D00321	Finasteride	G04CB01 D11AX10	DB01216

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Androgenetic Alopecia	Japan	Organon & Co.	11 Oct 2005
Alopecia	United States	Organon & Co.	19 Dec 1997
Prostatic Hyperplasia	United States	Organon & Co.	19 Jun 1992

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alopecia, Male Pattern	Phase 3	Belgium	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Phase 3	Germany	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Phase 3	Hungary	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Phase 3	Russia	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Phase 3	Spain	Polichem SA (Switzerland)	02 Aug 2016
Hematuria	Phase 2	Canada	Merck Frosst Canada Ltd.	01 Mar 2008
Hemospermia	Phase 2	Canada	Merck Frosst Canada Ltd.	01 Mar 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02248701 (Pubmed \| Front Neurol)	Phase 2	Spinal Cord Injuries testosterone \| estradiol \| dihydrotestosterone	12	High-dose Testosterone + Finasteride	einloauciz(kzzgkjgons) = reduced more than vehicle+placebo at 12 months cgjyzbgnhh (lkmxeoozei ) View more	Positive	11 Dec 2024
THU372 (ENDO2023)	Not Applicable	Hyperglycemia	-	Finasteride	ouxexqzyof(ihlcbeifmw) = qksbcjapgh tqrlnylsba (yqerhqtzoq )	Negative	05 Oct 2023
NCT02248701 (CTgov)	Phase 2	Hypogonadism \| Genital Diseases, Male \| Spinal Cord Injuries	33	Finasteride+Testosterone Enanthate (Testosterone Enanthate, Finasteride)	pbyauifwse(ledqbojjki) = ywuxevjivb qeuayuhtqf (vtgbxdsdci, 4.7) View more	-	29 Sep 2023
				Placebo pill (Placebo Treatment)	pbyauifwse(ledqbojjki) = smcqnpecot qeuayuhtqf (vtgbxdsdci, 2.4) View more
WCD2023	Not Applicable	Androgenetic Alopecia	28	Oral Minoxidil (2.5MG)	vmvtsprrgh(dwejiiibww) = etpnhooclb unhjksggoq (mhrltujnfq )	-	03 Jul 2023
				Oral Finasteride (1MG)	vmvtsprrgh(dwejiiibww) = ehuldrznmt unhjksggoq (mhrltujnfq )
EURETINA2022	Not Applicable	Central Serous Chorioretinopathy	-	Finasteride	vwsoncmzki(zscispwuxh) = bqfpgflwpj ufxeathwva (qrfrnomdmd )	-	01 Sep 2022
ARVO2022	Not Applicable	Dry Eye Syndromes	116	Finasteride 1 mg or 2.5 mg	porhhpiino(vhrhgnmblq) = urlchscevf vbjdhopltu (odbpdoqqip ) View more	-	01 May 2022
				Finasteride 5 mg	porhhpiino(vhrhgnmblq) = cumgmaptta vbjdhopltu (odbpdoqqip ) View more
MP38-07 (AUA2022)	Not Applicable	Sexual Dysfunction DHT \| testosterone \| calculated free T	91	Men with persistent sexual dysfunction after discontinuation of Finasteride	zimdhcorsm(aovuaqiebf) = rpkazboufy ufmtsjstbp (nqpdhaenfh ) View more	-	01 May 2022
NCT01342367 (Prospective Trial Of Oral-Only Hormonal Therapy With Radiation, CTgov)	Not Applicable	Non-metastatic prostate cancer	74	bicalutamide+goserelin+leuprolide (SOC Cohort)	nmsfhlabuy(msmvphwoux) = bvefznrrbq isjnpoiigt (wyrllauhck, 0.04) View more	-	28 Oct 2021
				finasteride+dutasteride+bicalutamide (Oral ADT Group)	nmsfhlabuy(msmvphwoux) = cxnrbklogg isjnpoiigt (wyrllauhck, 0.04) View more
NCT03004469 (CTgov)	Phase 3	Androgenetic Alopecia \| Alopecia, Male Pattern	458	P-3074+Finasteride Placebo (P-3074 + Finasteride Placebo)	hzsvvkcvfi(awjhangnhj) = xccylvxqbt usreegaszb (aqhqdfnuwo, 2.88) View more	-	19 Apr 2019
				Finasteride Placebo+P-3074 Vehicle (P-3074 Vehicle + Finasteride Placebo)	hzsvvkcvfi(awjhangnhj) = jkblptxtqz usreegaszb (aqhqdfnuwo, 3.01) View more
ASTRO2018	Not Applicable	Prostatic Cancer	-	Finasteride use prior to prostate cancer diagnosis	nqddeddpgv(bktrgjsbsp): HR = 1.03 (95% CI, 0.98 - 1.08), P-Value = 0.21 View more	-	01 Nov 2018
				No finasteride use prior to prostate cancer diagnosis

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis